Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) is a research paper published in Journal of Thoracic Disease (2021). On theSindex it has a DataRank of 0. It has been cited 16 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA218802
NCI NIH HHS
Grant: P30 CA060553
NCI NIH HHS
Grant: R21 CA223394
NCI NIH HHS
Grant: P30 CA006927
National Institutes of Health
Grant: 5P30CA006927-49
Transgenic Mouse
National Institutes of Health
Grant: 5P30CA060553-12
The Robert H.Lurie Comprehensive Cancer Center
National Institutes of Health
Grant: 5R01CA218802-04
Targeting Musashi-2 (MSI2) regulation of VEGFR2/VEGF-A in lung cancer
National Institutes of Health
Grant: 5R21CA223394-02
Targeting Musashi-2 (MSI2) regulation of EGFR and HER2 in lung cancer
FWCI
1.02
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition
Additional file 1 of Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition
Additional file 2 of Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition
Additional file 2 of Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition